FDA's New Fast-Track Drug Approval: Is It Safe or Just Speedy?

The FDA has introduced a new program that promises super-fast drug approvals. This program, called the Commissioner’s National Priority Voucher, can approve drugs in just one to two months. This is much faster than the usual 10-month review process. The idea is to prioritize drugs that match certain national goals, like making healthcare more affordable or securing the country’s drug supply. But here’s the catch: this program lets political leaders, not just scientists, decide which drugs get fast-tracked. Normally, the FDA focuses on whether a drug is safe and effective. This new program, however, also considers broader policy goals. Some worry this could mix politics with science, which might not be a good idea.

To get this fast approval, drug companies have to explain how their product fits one of five priorities. These include things like responding to public health crises or making drugs more affordable. A council led by the FDA commissioner reviews these applications, but career scientists aren’t involved in this part of the process. Once a voucher is granted, the usual scientists still review the drug’s safety and effectiveness. So far, 18 vouchers have been given out, covering areas like cancer and rare diseases. Some of these approvals have raised eyebrows, like vouchers for drugs related to infertility and obesity. Critics argue that this program could make people doubt whether drugs are approved based on science or politics. The FDA has a big job: making sure drugs are safe and effective. Mixing in policy goals could make people question their decisions. It’s important for the FDA to stay focused on science, not politics. Otherwise, people might start wondering if fast approvals are really the best idea.

Actions